|Bid||75.00 x 800|
|Ask||86.45 x 800|
|Day's Range||82.56 - 83.76|
|52 Week Range||60.27 - 153.99|
|Beta (3Y Monthly)||2.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||117.00|
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. Warning! GuruFocus has detected 3 Warning Signs with ALNY. For the last quarter Alnylam Pharmaceuticals Inc reported a revenue of $21.0 million, compared with the revenue of $37.92 million during the same period a year ago.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 15. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $4.95 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Alnylam (ALNY) delivered earnings and revenue surprises of 7.61% and 67.92%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of $2.09 per share. Losses, adjusted for stock option expense, came to $1.82 per share. The results topped Wall Street expectations. The average ...
− Achieved Fourth Quarter 2018 ONPATTRO® Global Net Product Revenues of $12.1 Million, with Over 200 Patients on Commercial Product in U.S. and EU as of Year-End 2018 –
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that results from the Phase 1 study of givosiran, an investigational, subcutaneous RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyria (AHP), were published online today in The New England Journal of Medicine (NEJM). The full manuscript, titled “Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria,” will appear in the February 7, 2019 issue of NEJM.
Alnylam (ALNY) is leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to improve the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2018 on Thursday, February 7, 2019, after the U.S. financial markets close. To access the call, please dial 800-667-5617 (domestic) or 334-323-0509 (international) five minutes prior to the start time and refer to conference ID 4263166. To access the replay, please dial 888-203-1112 (domestic) or 719-457-0820 (international) and refer to conference ID 4263166.
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location,” said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals.
NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.